{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:15:24Z","timestamp":1775848524669,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.jcv.2011.10.003","type":"journal-article","created":{"date-parts":[[2011,11,21]],"date-time":"2011-11-21T20:47:14Z","timestamp":1321908434000},"page":"65-71","source":"Crossref","is-referenced-by-count":21,"title":["Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma"],"prefix":"10.1016","volume":"53","author":[{"given":"Tatiana","family":"Plavina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses","family":"Njenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid","family":"Gorelik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Schlain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meena","family":"Subramanyam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2011.10.003_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jcv.2011.10.003_bib0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2165\/11537510-000000000-00000","article-title":"Progressive multifocal leukoencephalopathy and newer biological agents","volume":"33","author":"Berger","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.jcv.2011.10.003_bib0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jcv.2011.10.003_bib0020","unstructured":"Guidance for Industry on Bioanalytical Method Validation, prepared by the Biopharmaceutics Coordinating Committee in the Center for Drug Evaluation and Research (CDER) in cooperation with the Center for Veterinary Medicine (CVM) at the Food and Drug Administration (USA) May 2001."},{"key":"10.1016\/j.jcv.2011.10.003_bib0025","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1023\/B:PHAM.0000003390.51761.3d","article-title":"Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules","author":"DeSilva","year":"2003","journal-title":"Pharm Res"},{"key":"10.1016\/j.jcv.2011.10.003_bib0030","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","article-title":"Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors","volume":"199","author":"Egli","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2011.10.003_bib0035","doi-asserted-by":"crossref","first-page":"11170","DOI":"10.1128\/JVI.79.17.11170-11178.2005","article-title":"Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides","volume":"79","author":"Krymskaya","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jcv.2011.10.003_bib0040","series-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Validation of analytical procedures: text and methodology Q2(R1)","first-page":"5","year":"2005"},{"key":"10.1016\/j.jcv.2011.10.003_bib0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.virol.2010.07.046","article-title":"Prevalence and stability of antibodies to 37 human papillomavirus types \u2013 a population-based longitudinal study","volume":"407","author":"Antonsson","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.jcv.2011.10.003_bib0050","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ana.22137","article-title":"JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab","volume":"68","author":"Ryschkewitsch","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jcv.2011.10.003_bib0055","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/jmv.21493","article-title":"Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients","volume":"81","author":"Grabowski","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/j.jcv.2011.10.003_bib0060","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1099\/vir.0.18842-0","article-title":"Seroepidemiology of human polyoma viruses","volume":"84","author":"Stolt","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jcv.2011.10.003_bib0065","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/jnci\/djg074","article-title":"Lack of serologic evidence for prevalent simian virus 40 infection in humans","volume":"95","author":"Carter","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jcv.2011.10.003_bib0070","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jmv.21710","article-title":"Characterization of JC human polyomavirus infection in a Portuguese population","volume":"82","author":"Matos","year":"2010","journal-title":"J Med Virol"},{"key":"10.1016\/j.jcv.2011.10.003_bib0075","doi-asserted-by":"crossref","first-page":"e1000363","DOI":"10.1371\/journal.ppat.1000363","article-title":"Seroepidemiology of human polyomaviruses","volume":"5","author":"Kean","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jcv.2011.10.003_bib0080","series-title":"Tysabri [prescribing information]","year":"2011"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653211004215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653211004215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T04:50:12Z","timestamp":1543380612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653211004215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1386653211004215"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2011.10.003","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}